Editorial Board Member - JCS
Dr. Peter Parker was trained as an undergraduate in Biochemistry (BA) at Oxford and then as a post-graduate under Professor Sir Philip Randle in Clinical Biochemistry (D.Phil) at Oxford. He subsequently won an MRC Post-Doctoral Fellowship to work with Professor Sir Philip Cohen in Dundee and following this started working in the area of oncology as an ICRF (now CRUK) Fellow with Professor Mike Waterfield in London. Professor Parker has run an independent cancer research group since 1986 publishing over 300 primary research articles and reviews in the area of cancer and signal transduction.
Dr. Peter Parker has been recognised for his research contributions having been elected to the European Molecular Biology Organisation in 1995, to the Academy of Medical Sciences in 2000, he was awarded the Morton Prize in 2004 and elected to the Royal Society in 2006 and the EACS in 2011. Peter is Head of the Division of Cancer Studies at King’s College London, Deputy Director and R&D lead for the KHP Integrated Cancer Centre and is a Principal Scientist at the London Research Institute.
Dr. Peter Parker has ongoing research activities in oncology with expertise in signal transduction, molecular cell biology, biomarker research and drug discovery. Peter Parker has co-founded two biotechnology companies (co-founder of Piramed and of Symansis) and retains active links to biotech and pharma in the pursuit of delivering new interventions in the clinic.
Protein kinase C
Cancer cell biology
Other Editorial Board Members - JCS
Department of Human and Molecular Genetics
Massey Cancer Center
Department of Pathology
Smt. Kashibai Navale Medical College and General Hospital
University of New South Wales
Mitchell Cancer Institute
Cancer Science Institute of Singapore
National University of Singapore
Departments of Chemistry and Biology
Cleveland State University
School of Life Science
University of Science and Technology
Division of Hematology and Oncology
Indiana University School of Medicine